Clinical Trial Translation Services: Documents, Requirements, and Quality Standards

Key Takeaways

• Clinical trial translation covers a broad set of documents — protocols, informed consent forms (ICFs), case report forms (CRFs), patient-reported outcomes (PROs), investigator brochures, and site staff training materials — each with different regulatory requirements and quality standards.
• ICH E6 (R3), the Good Clinical Practice (GCP) guideline that came into effect in January 2025, sets out the framework within which clinical trial translation must operate. Informed consent forms in particular must be in a language understandable to the trial subject.
• Back-translation is required for patient-facing documents including ICFs and PRO instruments. It is not optional in GCP-compliant trials.
• Terminology consistency across languages and across sites is a data integrity issue, not just a linguistic preference. Inconsistent MedDRA coding or adverse event terminology across sites creates problems in aggregate safety data.
• Translation must be planned as part of the trial startup timeline. Last-minute translation orders are the most common cause of site activation delays in multinational trials.

Clinical trials are multinational by design. Phase II and Phase III studies routinely run across dozens of sites in multiple countries, with investigators, site staff, and trial subjects who work in different languages. Every document that a site receives, that a patient reads, or that a regulator reviews must be accurate in the language of its recipient — and consistent with every other language version.

The translation workload for a multinational trial is substantial. A Phase III oncology study running across 15 countries will generate hundreds of translated documents across the trial lifecycle, from initial protocol translation for ethics submissions through to final site closure documentation. Each document type carries its own regulatory requirements, quality standards, and turnaround constraints.

This guide covers what clinical trial translation involves, which documents require translation, what GCP requires, and what to look for when selecting a provider.

What Is Clinical Trial Translation?

Clinical trial translation is the specialist translation of documentation produced for the conduct of a clinical study — from the protocol that defines how the trial is run, to the consent forms that patients sign before participating, to the data collection tools that capture clinical outcomes.

It differs from other forms of medical translation in several important ways:

Regulatory governance. Clinical trial translation operates within a defined regulatory framework — primarily ICH E6 (Good Clinical Practice), the EU Clinical Trials Regulation (EU 536/2014), FDA requirements under 21 CFR Parts 50 and 312, and national ethics committee requirements. These set out specific obligations for certain document types, particularly informed consent.

Data integrity implications. In a clinical trial, inconsistent terminology across language versions is not merely a linguistic problem. If adverse events are described differently in English, German, and Japanese versions of a CRF, aggregate safety data becomes unreliable. Terminology consistency is a data integrity issue.

Speed constraints. Trial startup timelines are tightly managed. Ethics committee submission deadlines, site initiation visit schedules, and first patient in targets are all time-critical. Translation delays directly delay trial activation and, by extension, drug development timelines.

Multi-document programmes. A single trial generates translation requirements across its entire lifecycle — startup, conduct, amendments, safety reports, and closeout. Managing a clinical trial translation programme requires a provider that can handle volume, maintain consistency across documents, and respond quickly to protocol amendments.

Which Documents Require Translation in a Clinical Trial?

Informed Consent Forms (ICFs)

The informed consent form is the most heavily regulated document in clinical trial translation. ICH E6 (R3) requires that potential trial subjects receive information about the study in a language that is understandable to them, and that consent be obtained before any trial-related procedures are performed.

This means the ICF must be translated into the language of every country where the trial runs — and where a country has multiple official languages or significant patient populations speaking minority languages, additional translations may be required.

ICFs also require back-translation: the translated document is independently retranslated into the source language by a second translator who has not seen the original. Discrepancies between the back-translation and the source identify meaning errors that would not be apparent from a linguistic review alone. Ethics committees in most jurisdictions require back-translation to be submitted with the ICF.

Patient-friendly language is a specific requirement for ICFs — the document must be written and translated at a reading level appropriate to the anticipated patient population, not at the level of the clinical investigators. This adds a readability and lay-language review step that is not required for other document types.

Clinical Trial Protocols

The protocol defines the study design, objectives, endpoints, eligibility criteria, treatment schedule, assessments, and statistical analysis plan. In most multinational trials, the protocol is written in English and submitted to regulatory authorities and ethics committees in that language — but many jurisdictions require a translation of at least a summary or abstract for ethics committee review, and some require a full translation of the protocol.

Investigators and site staff at non-English-speaking sites also need access to a protocol translation for day-to-day trial conduct. Site staff who do not read English fluently may make protocol deviations simply because they have misunderstood an English-language procedure — a problem that translated protocols directly prevent.

Protocol amendments must be translated promptly when issued. An amendment that affects eligibility criteria or dosing procedures must reach all sites in their working language before they continue enrolling or treating subjects.

Case Report Forms (CRFs)

CRFs capture the clinical data collected at each study visit. In paper-based and hybrid trials, the CRF must be in the site’s working language. In electronic data capture (EDC) systems, the interface and data entry fields must be available in the local language.

CRF translation requires close attention to terminology. Data fields must use consistent terminology aligned with the medical coding dictionaries used for data analysis — MedDRA for adverse events and medical history, WHO Drug Dictionary for concomitant medications. A translated CRF that uses non-standard terminology for adverse event descriptions creates downstream coding problems when the data is aggregated.

Patient-Reported Outcomes (PROs) and ePROs

PRO instruments — questionnaires that capture how patients feel or function — are among the most demanding translation tasks in clinical research. FDA and EMA guidance requires that PRO instruments used in regulatory submissions be linguistically validated in each language version, not merely translated.

Linguistic validation follows a defined methodology: forward translation by two independent translators, reconciliation, back-translation, cognitive debriefing with members of the target patient population, and a final review. This process verifies not only that the translation is linguistically accurate but that patients in the target language understand the questions in the same way as patients in the source language.

For established PRO instruments with existing validated translations, sponsors may be able to license those translations rather than commissioning new ones. For novel PRO instruments developed for a specific trial, full linguistic validation in every trial language is required.

Investigator Brochure (IB)

The Investigator Brochure compiles the pre-clinical and clinical data on the investigational product relevant to its study in human subjects. It is primarily an English-language document, but investigators at non-English-speaking sites need to be able to read and understand it. A translated IB — or at minimum a translated summary — supports investigator training and ongoing reference during trial conduct.

IBs are updated during the trial as new safety data emerges. Translations must be updated in parallel with any IB revision that affects safety information for subjects or investigators.

Site Staff Training Materials

Site coordinators, nurses, and other site staff involved in trial conduct need training materials in their working language — training slides, procedure manuals, pharmacy manuals, laboratory handling instructions. The quality of site staff training directly affects protocol compliance and data quality. Materials that are poorly translated or in a language site staff do not read confidently are a recognised source of protocol deviations.

Regulatory and Ethics Submissions

Ethics committee submissions vary by country in their language requirements. Some require a full translated protocol; others accept English with translated summaries. Regulatory submissions to national competent authorities — required under EU CTR for initial authorisation and substantial modifications — must be in the language specified by the national authority.

Post the EU Clinical Trials Regulation (EU 536/2014), submissions to the Clinical Trials Information System (CTIS) are coordinated centrally, but the reporting member state and concerned member states each have their own language requirements for specific document types.

What GCP Requires from Clinical Trial Translation

ICH E6 (R3), finalised in January 2025, updates the GCP framework that governs clinical trial conduct across ICH member regions (EU, US, Japan, and others). On translation, the key requirements are:

Informed consent: The subject must receive information in a language they understand. The consent process must be conducted in that language. The signed consent form must be in that language.

Comprehension: ICH E6 (R3) strengthens the requirement that information be comprehensible — not merely translated. For patient-facing materials, translation into technically correct but inaccessible language does not satisfy the requirement.

Documentation: The investigator must document that consent was given in accordance with GCP requirements, including that the subject received and understood the information in their own language.

Site staff competence: Staff involved in trial conduct must be qualified by training and experience to perform their assigned functions. Where those functions require reading and understanding trial documents, those documents must be available in a language in which the staff are competent.

The EU Clinical Trials Regulation (EU 536/2014) adds specific requirements for the languages used in ethics committee submissions and informed consent documents in EU member states.

Back-Translation: What It Is and When It Is Required

Back-translation is the process of translating a document back into the source language, independently and without reference to the original, to verify that the translated meaning matches the source meaning.

It is required for:

• Informed consent forms
• PRO instruments (as part of linguistic validation)
• Patient diaries and questionnaires
• Any other patient-facing document where meaning equivalence across languages must be demonstrated to a regulatory authority or ethics committee

It is not routinely required for:

• Protocol translations
• CRF translations
• Site staff training materials
• Regulatory submission documents

Back-translation identifies errors that forward translation review alone would not catch — particularly where an ambiguous phrase in the source has been resolved differently in the target language, or where culturally specific content has been handled in a way that shifts meaning.

The back-translation must be performed by a translator who has not seen the source document. Any significant discrepancies between the back-translation and the original must be documented, adjudicated, and resolved before the document is finalised.

Terminology Management in Clinical Trial Translation

Terminology consistency across a multinational trial is not a cosmetic requirement. It directly affects the integrity of the clinical data.

MedDRA coding. Adverse events and medical history are coded to the Medical Dictionary for Regulatory Activities (MedDRA) in all regulatory submissions. If site staff in different countries describe the same adverse event in different terms — because their local language CRF uses different terminology — the data management team must reconcile those descriptions before coding. Inconsistent adverse event terminology across sites increases the data cleaning burden and can introduce coding errors.

Endpoint definitions. Primary and secondary endpoints must be assessed and recorded consistently across all sites and all languages. A translated endpoint definition that subtly changes the assessment criteria creates cross-site variability in outcome data.

Approved terminology lists. For large multinational trials, a sponsor-approved clinical terminology list — covering endpoint definitions, adverse event descriptions, and procedure names — should be developed before translation begins and used by all translators working on the programme.

Translation memory. A translation memory built across the trial lifecycle ensures that the same phrase is always translated the same way. When the protocol is amended, the translation memory flags existing approved translations for unchanged content and highlights only new or changed text for translation — reducing both cost and inconsistency.

Planning Clinical Trial Translation: Avoiding Startup Delays

Translation is consistently identified as a cause of trial startup delays in multinational studies. The most common reasons:

Translation ordered too late. ICF translation for ethics committee submission is frequently commissioned after the protocol is finalised, leaving insufficient time for translation, back-translation, and ethics committee review before the target first patient in date.

Amendments not routed for translation. Protocol amendments are sometimes approved and distributed to English-language sites before translations are commissioned. Non-English-speaking sites receive amendments they cannot act on, creating compliance gaps and potential protocol deviations.

Insufficient budget for the full programme. Translation budgets for clinical trials are sometimes set against the initial document volume without accounting for amendments, safety updates, IB revisions, and closeout documentation. Mid-trial budget constraints lead to delays when additional translation is needed urgently.

Provider changes mid-trial. Changing translation providers during a trial introduces terminology inconsistency. The new provider does not have access to the translation memories and termbase built during the earlier phases, and translated documents will not be consistent with site-level materials already in use.

The solution is to plan the translation programme as part of the trial startup plan — identifying all document types, all languages, approximate volumes and timelines, and selecting a single provider who can handle the full programme with a dedicated team and maintained translation memory.

How Global LTS Supports Clinical Trial Sponsors and CROs

At Global LTS, our medical translation services include full clinical trial translation support for pharmaceutical sponsors, biotechnology companies, and Contract Research Organisations (CROs) running studies in the UK, EU, and internationally.

We provide:

• ICF translation and back-translation in all EU languages and beyond
• Protocol and protocol amendment translation
• CRF and eDC interface translation with MedDRA-aligned terminology
• PRO and ePRO linguistic validation coordination
• Investigator Brochure translation and update management
• Site staff training material translation
• Regulatory and ethics submission document translation
• Ongoing programme management with dedicated translation memory and termbase

We work to GCP-compliant quality processes under ISO 17100, with subject-specialist translators experienced in clinical research documentation. Our 120+ language coverage includes all EU languages, Japanese, Mandarin, Korean, Arabic, and other regulated market languages.

Contact us to discuss your clinical trial translation requirements and receive a programme proposal.

Frequently Asked Questions

Is back-translation required for all clinical trial documents?
No. Back-translation is required for informed consent forms and PRO instruments, and is recommended for any patient-facing document. It is not routinely required for protocol translations, CRF translations, or site staff documentation.

What languages are required for an EU clinical trial?
EU CTR requires informed consent documents in the official language of each member state where the trial is conducted. The specific requirements vary by member state and document type. Ethics committees in some countries accept English for investigator-facing documents but require the national language for patient-facing materials.

How does GCP E6(R3) affect clinical trial translation requirements?
ICH E6 (R3), finalised in January 2025, strengthens the requirement that trial subjects receive information in a language they understand and that the information is comprehensible — not merely translated. It also reinforces documentation requirements around the consent process and the language in which it was conducted.

What is linguistic validation and when is it required?
Linguistic validation is a multi-step process — forward translation, back-translation, and cognitive debriefing — used to verify that a PRO instrument measures the same construct in the target language as in the source language. It is required for PRO instruments used in regulatory submissions. It is not required for standard trial documents such as protocols or CRFs.

Can we use machine translation for clinical trial documents?
Machine translation output requires post-editing by a qualified human translator before it can be used in GCP-compliant clinical trial documentation. Raw machine translation is not acceptable for regulatory submissions, ethics committee applications, or patient-facing documents. For high-volume, low-risk content such as site correspondence, machine translation with human post-editing may be appropriate.

How far in advance should we commission ICF translations?
For a standard ethics committee submission timeline, ICF translations should be commissioned at least four to six weeks before the submission deadline to allow for translation, back-translation, reconciliation, and any necessary revision. For studies running in many countries simultaneously, commission earlier — eight to ten weeks is more realistic when multiple language pairs need to be managed in parallel.